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CASE REPORT
Immune checkpoint inhibitor therapy in HIV-
associated Merkel cell carcinoma: A case series
of 3 patients
Song Y. Park, MD,a Candice Church, PhD,a Nora A. Alexander, BS,a Michi M. Shinohara, MD,a
Kelly G. Paulson, MD, PhD,b Karl D. Lewis, MD,c Nancy S. Lee, MD,d and Paul Nghiem, MD, PhDa
Seattle/Edmonds, Washington; Aurora, Colorado; and San Diego, California
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INTRODUCTION
Merkel cell carcinoma (MCC) is an aggressive skin
cancer, which is about twice as likely to metastasize
as compared with melanoma.1 There are 2 distinct
biological pathways for developingMCC: Merkel cell
polyomavirus (MCPyV)-induced and ultraviolet
light-induced.2 In individuals immunosuppressed
by HIV infection, the risk of developing MCC is
13-fold higher than for the general population.1
Historically, outcomes have been dismal, with a
2-year disease-specific survival rate of 0% in 1
published case series.3
Recently, anti-programmed cell death 1 (PD-1)
and anti-programmed death ligand 1 (PD-L1) agents
in immunocompetent patients with advanced MCC
(aMCC) demonstrated a ;60% response rate and a
durable benefit in the majority of responding pa-
tients.4 Based on these data, these agents have
emerged as the treatment of choice for aMCC.
However, immunosuppressed individuals, including
those who are HIV-positive, have been excluded
from clinical trials with anti-PD-(L)1 agents due to
concerns about efficacy and potential for inadvertent
augmentation of infectious and/or inflammatory
activity.5 It is, therefore, unknown whether immune
checkpoint inhibitors (ICI), including anti-PD-(L)1
treatment, are effective for HIV-positive patients with
aMCC.
To better understand the clinical and biological
features of HIV-positive aMCC patients treated with
ICI, we performed a comprehensive review of our
Seattle-based IRB-approved repository of MCC pa-
tient data and specimens. We have also described
biomarker analyses, including immune cell infiltra-
tion, tumor MCPyV status, and intratumoral expres-
sion of PD-1 and PD-L1.
CASE REPORT
Among the ;1500 MCC patients diagnosed be-
tween 1980 and 2020, we identified 10 patients with a
history of HIV at the time of their MCC diagnosis.
Distant metastatic disease eventually developed in
all the 10 patients. Among these patients, 3 were
treated with ICI therapy.
Abbreviations used:
aMCC: advanced Merkel cell carcinoma
CR: complete response
ICI: immune checkpoint inhibitors
IHC: immunohistochemistry
MCC: Merkel cell carcinoma
MCPyV: Merkel cell polyomavirus
PD-1: anti-programmed cell death-1
PD-L1: anti-programmed death ligand-1
PET: positron emission tomography
RT: radiation treatment
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Patient 1 was a 55-year-old man who was initially
diagnosed with MCC involving the right neck and
parotid gland. The patient underwent a parotidec-
tomy and neck dissection, followed by adjuvant
radiation treatment (RT) of both the right parotid
and right side of the neck. Ten months after
diagnosis, metastatic disease developed in the pa-
tient’s abdomen and peritoneum.
The patient was diagnosed with HIV 30 years
earlier. Over this period, he had been treated with an
antiretroviral regimen consisting of ritonavir, daru-
navir, raltegravir, emtricitabine, tenofovir, and alafe-
namide. His HIV viral load was consistently
undetectable; however, his CD4 count persistently
remained in the AIDS-defining range of 150-
200 cells/mm3. He had a history of oral candidiasis
but no other recent AIDS-defining illnesses.
The patient was offered pembrolizumab every
3 weeks. A positron emission tomography/
computed tomography (PET/CT) scan following 4
cycles showed a complete response (CR) with reso-
lution of PET-avid disease (Fig 1,A,B). Besides grade
1 fatigue, the patient tolerated immunotherapy well
without any major side effects. After 26 months of
treatment and maintaining a CR, the patient decided
to stop infusions. Three months later, the patient
restarted pembrolizumab, when he developed a
minimally fluorodeoxyglucose-PET-avid lesion in
the right aspect of the neck. The patient’s previous
MCC was highly fluorodeoxyglucose-avid at
diagnosis (typical for MCC in general), but pembro-
lizumab was restarted for possible disease
recurrence. Biopsy was not performed as per the
patient’s wish. In the PET/CT 4months later, the right
neck lesion remained stable, but it resolved 1 year
later. Since resuming pembrolizumab, he has
remained without clinically detectable disease at
45 months from the initial diagnosis of metastasis.
His HIV status and CD4 levels are stable, and his viral
load remained undetectable throughout his treat-
ment course.
Biomarker and immunohistochemistry (IHC) anal-
ysis of the pretreatment, formalin-fixed, paraffin-
embedded tumor biopsy samples of the patient’s
metastatic MCC were performed at the Fred
Hutchinson Cancer Research Center Histopathology
Lab and assessed by a dermatopathologist (M.M.S.).
Despite low peripheral CD41 counts (128 cell/mm3
on the day of biopsy), intratumoral CD81 (infiltration
score of 3; 434-582 cells/mm3)6 and CD41 T cells
were observed (12 cells/mm2 intratumorally) (Fig 1,
C, D). Furthermore, tumor biopsy sections were
positive for PD-1 and PD-L1 expression (Fig 2, D,
E ).7,8 IHC expression of MCPyV large T antigen
(Santa Cruz Biotechnology clone CM2B4) was
negative, which suggests that the patient’s MCC
tumor was virus-negative MCC (Fig 2, C ).
Patient 2
Patient 2 was a 64-year-old man who was initially
diagnosed with MCC involving a 6-cm tumor of the
left buttock, which spread to the ipsilateral inguinal
lymph nodes. The patient underwent removal of the
involved lymph nodes, followed by RT. Nine months
after the initial diagnosis, metastatic disease devel-
oped in the left leg muscles and adenopathy along
the left iliac chain and retroperitoneum.
The patient’s HIV infection had been diagnosed
[30 years earlier. Antiretroviral therapy included
darunavir, dolutegravir, and raltegravir. The HIV viral
load was consistently undetectable, with a stable
CD4 count between 1500 and 1600 cells/mm3. The
patient experienced a decrease in the CD4 count to
500 cells/mm3 after RT, which gradually recovered to
about 700 cells/mm3.
The patient received pembrolizumab every
3 weeks. A CT scan following 5 cycles of immuno-
therapy showed CR (Fig 1, E, F ). The patient
tolerated the treatment well without any major side
effects. He continues to have no detectable disease
after 22 months of pembrolizumab treatment. His
HIV status and CD4 levels are stable, and his viral
load remained undetectable throughout the treat-
ment course.
Biomarker and IHC analyses of the pretreatment
tumor biopsy samples of his aMCC were performed
in the same manner as for patient 1. Intratumoral
CD81 (infiltration score of 2; 180-433 cells/mm3)
and CD41 T cells were observed (7 cells/mm2
intratumorally) (Fig 1, G, H ). Tumor biopsy sections
were positive for expression of PD-1 and PD-L1
(Fig 2, H, I ). IHC expression of MCPyV large T
antigen was positive (Fig 2, G).
Patient 3
Patient 3 was a 64-year-old man who was
initially diagnosed with MCC of the posterior scalp
with microscopic involvement of the ipsilateral
neck lymph nodes. The patient underwent wide
local excision of the primary lesion, sentinel lymph
node biopsy, and RT of the scalp and neck.
However, his disease continued, and multiple
lesions developed on his scalp, liver, and bone
lesions. He received an 8-Grey single-fraction
RT to the skin lesions, followed by 2 cycles of
chemotherapy with carboplatin and etoposide with
short-term benefit.
The patient’s HIV infection had been
diagnosed 9 years before and was treated with
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efavirenz-emtricitabine-tenofovir. His HIV viral
load remained consistently undetectable, with a
stable CD4 count between 500 and 700 cells/mm3.
Within 2 months of completion of chemo-
therapy, the patient’s disease progressed, and he
started pembrolizumab. The patient’s MCC
continued progressing, despite the addition 1 dose
of ipilimumab. Radioactive sphere embolization of
the liver was added one month later, with continued
infusion of pembrolizumab every 3 weeks. Despite
multiple lines of immunotherapy, the patient’s MCC
progressed. Unfortunately, his disease did not
Fig 1. Changes in patient 1 MCC tumor size in the right aspect of the mid-abdomen
(2.6 3 1.7 cm), which resolved after 4 doses of pembrolizumab treatment (A, B), and IHC of
pretreatment tissue demonstrating moderate intratumoral CD41 and CD81 immune infiltrate
(C, D). Changes in patient 2 MCC tumors near the aortoiliac bifurcation (L, 2.9 3 1.5 cm; R,
2.5 3 2.2 cm), which resolved after 10 months of pembrolizumab treatment (E, F), and IHC
stains demonstrating intratumoral CD41 and CD81 immune infiltrate (G, H). IHC, Immuno-
histochemistry; MCC, Merkel cell carcinoma.
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respond to subsequent therapies, and the patient
succumbed to disease 4 months after initiating
pembrolizumab. His MCC was MCPyV-positive,
which was confirmed by an MCPyV-specific onco-
protein antibody test.9 Tumor tissue was not avail-
able for analysis.
Fig 2. IHC of pretreatment tissue. Patient 1 (A-E). A, Hematoxylin-eosin staining of the tumor
tissue demonstrating a poorly differentiated, pleomorphic neuroendocrine carcinoma (original
magnification: 320.) B, Positive synaptophysin. C, Negative Merkel cell polyomavirus large T
antigen expression (clone CM2B4). D, Positive PD-1 expression. E, Positive PD-L1 expression
(original magnification:320). Positivity for PD-L1 was defined as[1% expression by tumor or
immune cells7 and positivity for PD-1 defined as any expression observed in the tumor
infiltrating lymphocytes.8 Patient 2 (F-I). F, Hematoxylin-eosin staining of the tumor tissue
demonstrating a poorly differentiated, pleomorphic neuroendocrine carcinoma (original
magnification: 320). G, Positive Merkel cell polyomavirus large T antigen expression within
the tumor. H, Positive PD-1 expression. I, Positive PD-L1 expression (original magnification:
320, except for PD1 expression to show junction between the inflammation and the tumor in a
lymph node). IHC, Immunohistochemistry; PD-1, anti-programmed cell death 1; PD-L1, anti-
programmed death ligand 1.
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Table I. Comparison of case reports describing the use of anti-PD-(L)1 for metastatic MCC in patients with HIV
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Patient 1 55 M 0 Pembrolizumab
2 mg/kg q3w













Patient 2 64 M 0 Pembrolizumab
2 mg/kg q3w







Undetectable None CR 22 22
Patient 3 64 M 0 Pembrolizumab
2 mg/kg q3w,
ipilimumab





































39 M 0 Avelumab














































CR, Complete response; ECOG, Eastern Cooperative Oncology Group; F, female; ICI, immune checkpoint inhibitor; IRAEs, immune-related adverse events; M, male; MCC, Merkel cell carcinoma; OS,
overall survival; PD, progressive disease; PFS, progression-free survival.
*After 26 months of pembrolizumab treatment and maintaining a CR, the patient stopped infusions. An fluorodeoxyglucose-PET-avid lesion developed in the right side of his neck 3 months later.
The lesion was not biopsied, and patient resumed pembrolizumab. The neck lesion in the right side remained stable in the subsequent PET/CT scans and had resolved 1 year later. The patient

































While anti-PD-(L)1 agents have become a stan-
dard treatment for aMCC, HIV-positive patients have
been excluded from most previous trials. Therefore,
limited data exist in terms of ICI use for HIV-positive
patients with aMCC.
In our cohort of ;1500 MCC patients, we identi-
fied 3 individuals with chronic HIV infection treated
with ICIs for aMCC. Despite a chronic AIDS-defining
low CD41 count, patient 1 experienced a durable CR
without any HIV or immune-related complications.
Interestingly, despite the HIV status, the patients
whose MCC disease responded to ICIs both had an
immune-favorable MCC tumor microenvironment,
including a CD81 infiltrated pattern of T cells and
PD-L1 expression of greater than 1%.
Unfortunately, one individual’s disease (patient 3)
progressed on multiple lines of ICI. It is possible that
bone marrow suppression, caused by 2 initial cycles
of chemotherapy, may have affected his response to
ICI. Multiple studies have shown that the response
rate to anti-PD-(L)1 agents after chemotherapy is
lower than for first-line systemic treatment in immu-
nocompetent patients.4 It is therefore plausible that
HIV-positive patients have a more beneficial
response to anti-PD-(L)1 for their aMCC, if it is
used as a first-line treatment.
Three other case reports in the literature describe
anti-PD-(L)1 responses for aMCC in patients with
HIV (Table I).10-12 To the best of our knowledge, the
cases reported here represent the longest follow-up
to date.
While we cannot estimate the overall response
rate based on our small number of cases, our data do
support that HIV-positive MCC patients can experi-
ence favorable responses to anti-PD-(L)1 agents.
This is further supported by a recent systematic
review of case reports of ICI use across different
malignancies, which found that ICIs had similar
objective responses in HIV-positive patients when
compared with HIV-negative patients.13
Pembrolizumab has been used for the treatment
of other cancers in individuals with HIV, and early
reports from the CITN-12 trial suggest that toxicity is
tolerable in those with HIV.14 Given the rarity of both
HIVand MCC, very few cases are observed in the US,
and a large prospective trial is not feasible. However,
given the demonstrated 0% MCC-specific 2-year
survival among 7 patients with HIV treated with
prior approaches,3 we believe that these findings
provide support for the use of PD-(L)1 inhibitors in
the first-line in patients with HIV and aMCC.
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